Analyst Price Target is $34.40
▲ +121.94% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for enGene in the last 3 months. The average price target is $34.40, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 121.94% upside from the last price of $15.50.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in enGene. This Buy consensus rating has held steady for over two years.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More